Congratulations on launching this and reaching your one year mark!! Starting a new charity sounds like a tremendous amount of work, and I have so much respect for CE incubatees.
Based on these factors, we believe that Ansh’s program can reduce neonatal mortality by at least 50%[10].
I had a nitpicky impact evaluation question, sorry if I’m missing something.
Is this 50% number based on your actual observed reduction in neonatal mortality, given your baseline of ~[13% to 27%]? Or is it based on the studies linked in the prior paragraph? I was just a bit surprised to see you cite these papers instead of your own preliminary data :)
It naively seems to me that since you have ~5 months of operational data (given a Jan 2024 launch) + 900 enrollments, maybe you can estimate your actual, tentative observed effects? (Looks like the Cochrane review paper gives some data on the health outcomes of infants at the point of being discharged + at the 1-3 month post discharge mark, so maybe you have some observed effects already?)
So reasonable if you just haven’t gotten around to this yet, or if there’s another consideration I haven’t thought of. Good luck with your work!!
Really good questions! You are absolutely right: we do have our own observed mortality data since a neonatal period is 28 days and we have been operating for almost 6 months now. We plan to discuss it thoroughly in our evaluation report that we are working on with some external partners. Since it’s observed mortality data, we want to ensure that it’s shared responsibly. Happy to share the report with you once its published (will take a few months).
Kind of curious if you looked into this—obviously no pressure to share before you’re ready though, I was just scrolling through some old comments :) Good luck on your work!
Congratulations on launching this and reaching your one year mark!! Starting a new charity sounds like a tremendous amount of work, and I have so much respect for CE incubatees.
I had a nitpicky impact evaluation question, sorry if I’m missing something.
Is this 50% number based on your actual observed reduction in neonatal mortality, given your baseline of ~[13% to 27%]? Or is it based on the studies linked in the prior paragraph? I was just a bit surprised to see you cite these papers instead of your own preliminary data :)
It naively seems to me that since you have ~5 months of operational data (given a Jan 2024 launch) + 900 enrollments, maybe you can estimate your actual, tentative observed effects? (Looks like the Cochrane review paper gives some data on the health outcomes of infants at the point of being discharged + at the 1-3 month post discharge mark, so maybe you have some observed effects already?)
So reasonable if you just haven’t gotten around to this yet, or if there’s another consideration I haven’t thought of. Good luck with your work!!
Hi Angelina,
Really good questions! You are absolutely right: we do have our own observed mortality data since a neonatal period is 28 days and we have been operating for almost 6 months now. We plan to discuss it thoroughly in our evaluation report that we are working on with some external partners. Since it’s observed mortality data, we want to ensure that it’s shared responsibly. Happy to share the report with you once its published (will take a few months).
Kind of curious if you looked into this—obviously no pressure to share before you’re ready though, I was just scrolling through some old comments :) Good luck on your work!